抗病毒藥品 Prevention of respiratory syncytial virus (RSV)

Monoclonal Antibody
Exhibits neutralizing and fusion-inhibitory activity against RSV; these activities inhibit RSV replication in laboratory and clinical studies

1. Bioavailability: 70%
2. Half-life elimination: 20 to 24.5 days
3. Time to peak, serum: 3 to 5 days; palivizumab concentrations sufficient to inhibit RSV 2 days after administration.
4. Excretion: Clearance is similar regardless of gestational age, though interpatient variability is high (48.7% coefficient of variation). Clearance may be slightly increased (~20%) in patients with chronic lung disease of prematurity or in the presence of antipalivizumab antibodies.

Significant prior hypersensitivity reaction to palivizumab or any component of the formulation.

Not for adult use.

Not for adult use.

Skin rash, Feve, Antibody development

Infants and Children <24 months:
1. IM: 15 mg/kg once monthly throughout RSV season; first dose administered prior to commencement of RSV season
2. If hospitalized at the start of RSV season, palivizumab should be given 48 to 72 hours before discharge or promptly after discharge.

There are no dosage adjustments provided in the manufacturer's labeling.

There are no dosage adjustments provided in the manufacturer's labeling.